A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects

BMC Infectious Diseases

Table 1 Cohort characteristics at baseline

Characteristic	Baseline value
Gender Female Male	(N = 9040) 5962 (66) 3078 (34)
Age (years) < 25 years 25-34 years 35-44 years 45-54 years > 55 years	(N = 9040) 551 (6.1) 3822 (42.3) 3216 (35.5) 1173 (13.0) 277 (3.1)
WHO AIDS classification Stage 1 Stage 2 Stage 3 Stage 4	(N = 8714) 4086 (46.9) 1310 (15) 2507 (28.8) 811 (9.3)
HAART d4T/3TC/EFV d4T/3TC/NVP d4T/3TC/Kaletra AZT containing regimen TDF containing regimen other	(N = 9040) 7138 (79) 690 (7.6) 669 (7.4) 308 (3.4) 59 (0.7) 176 (1.9)
BMI (kg/m ² )	22.4 ± 5.0 (N = 7010)
CD4 count (cells/mm ³ )	81 (29-149) (N = 7605)
Follow up time on HAART (months)	19.0 (9.1-31.6) (N = 9040)

Data is expressed as N (%) except for BMI (mean ± SD), CD4 count (median, IQR) and follow up time on HAART (median, IQR). WHO, World Health Organization, d4T, stavudine; 3TC, lamivudine; EFV, efavirenz; NVP, nevirapine; kaletra, ritonavir/lopinavir; AZT, zidovudine; TDF, tenofovir.

ISSN: 1471-2334